UNSPSC 51182022: Clostebol

This classification denotes an anabolic steroid with the molecular formula C19H27ClO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z7D4G976SH, chemically known as testosterone, 4-chloro-, acetate but generally known as clostebol, which bears US NIH Compound Identifier 13327. European Medicines Agency schedules Clostebol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06771MIG.

UNSPSC 51182022 Clostebol, a Commodity code, addresses the procurement of anabolic steroid pharmaceuticals for government healthcare systems and institutional use. State and local governments solicit this code as part of broader generic multi-source pharmaceutical purchasing vehicles that consolidate demand across multiple jurisdictions and agency types — state health departments, correctional facilities, public health clinics, and other state-administered healthcare programs. The work involves manufacturing and supply of clostebol (a synthetic anabolic steroid with therapeutic applications in certain medical contexts) through authorized pharmaceutical wholesalers, with vendors required to maintain current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, and FDA approval. Procurement emphasizes pricing competitiveness, product availability through established supply chains, regulatory compliance, and electronic data interchange capability for inventory management and ordering.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (S1070000015802) on January 20, 2026, due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon. Vendors must supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), maintain contractual relationships with at least two of the three, and comply with extensive insurance requirements including $5 million commercial general liability and $2 million network security and privacy liability. The contract term runs two years for new responders with optional extensions; pricing evaluation is weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and remaining points on administrative compliance, EDI capability, and willingness to accept a 3 percent administrative fee. All awarded products must be available in the marketplace by May 15, 2026, with agreements effective July 1, 2026.